Key Highlights

  • Shares were trading down 19.73% at USD 0.85 in pre-market on Friday, November 13, 2026, implying a prior close near USD 1.06 (calculated); no company announcement explaining the move was found.
  • Ainos completed delivery of 1,400 AI Nose systems to semiconductor customer ASE under a three-year agreement worth USD 2.1 million, according to a September 2026 update.
  • The VELDONA technology transfer was confirmed on September 29, 2026, triggering an initial USD 600,000 license payment, with further payments tied to milestones.
  • Cash was about USD 1.4 million on June 30, 2026 against roughly USD 1.45 million of operating cash used in the second quarter, in a published review. The figure comes from one published review and is not confirmed against the filing.

A 19.73% Slide With No Fresh Announcement

Ainos (NASDAQ:AIMD) was trading down 19.73% at USD 0.85 in pre-market on Friday, November 13, 2026, per the extended-hours screener. No company announcement, filing or analyst action dated November 11 to November 13 was found to explain it. Third-quarter results are expected in November, and market calendars estimated November 11 to November 13, but the company had not confirmed a date in the material found. A published review put the shares near USD 0.63 on October 30, so the prior close near USD 1.06 (calculated) would mean a sharp rise before this fall. Thin trading can exaggerate such swings. Without a confirmed trigger, the move should be treated as price action rather than a reaction to company news, and it may reverse in the regular session.

AI Nose and VELDONA: What the Company Has Announced

Ainos describes itself as a dual-platform company in AI-based smell technology and immune therapeutics. Its AI Nose system digitizes scent into machine-readable data for semiconductor, robotics and smart Manufacturing use, and it has delivered 1,400 units to ASE under a USD 2.1 million, three-year agreement. A VELDONA license with BioPhoenix signed in late September carries a potential USD 10 million collaboration framework. VELDONA is a low-dose oral interferon platform, and its technology transfer triggered an initial USD 600,000 payment. No follow-on AI Nose orders were reported in the material found, and potential figures are not guaranteed revenue. The ASE contract equals about USD 700,000 a year (calculated), which is small against the USD 14.77 million loss reported for 2025.

Tiny Revenue, Thin Cash and Dilution Risk

Published market data showed 2025 Revenue of USD 124,157 and a net loss of USD 14.77 million, with a Market Value near USD 6.65 million on 7.38 million shares on October 21, 2026. Cash of about USD 1.4 million at June 30 set against quarterly operating cash use of roughly USD 1.45 million suggests a need for new funding, which for a small company often arrives through share sales that dilute holders. The 52-week range was USD 0.80 to USD 4.02 on that date. Next markers are the third-quarter report, cash after the USD 600,000 payment and any financing. The company also faces the usual listing pressure of a share trading below USD 1, though no deficiency notice was found in the material reviewed, and a reverse split remains a common response at such price levels.

Where Things Stand

Very little is known. No catalyst for the 19.73% pre-market drop at Ainos (NASDAQ:AIMD) was found, so it reads as a Reversal after a run from about USD 0.63 on October 30 to near USD 1.06 (calculated), possibly ahead of third-quarter results. The Business has real deliveries and license steps, but revenue is tiny, cash was about USD 1.4 million at June 30 and dilution is a standing risk. The next markers are the quarterly report, any financing and further AI Nose orders. Until the company reports or issues a statement, the cause of the move stays unverified, and no one should read it as a signal about the business.